April 1, 2021
Astellas Pharma has subsumed its wholly owned US subsidiary Audentes Therapeutics within the company and launched a new gene therapy center effective April 1. In January 2020, Astellas completed the acquisition of Audentes, which owns adeno-associated virus (AAV)-based gene therapy...read more